Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Rhea-AI Summary

Nuvalent, a clinical-stage biopharmaceutical company (Nasdaq: NUVL), has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event will take place on September 5, 2024, at 1:05 p.m. ET in New York City.

Key details:

• CEO James Porter, Ph.D., and CFO Alexandra Balcom will participate in a fireside chat
• A live webcast will be available on the company's website
• The webcast will be archived for 30 days after the presentation

Nuvalent focuses on developing precisely targeted therapies for clinically proven kinase targets in cancer. This conference participation provides an opportunity for investors and stakeholders to gain insights into the company's progress and future plans.

News Market Reaction – NUVL

+0.98%

1 alert

+0.98% News Effect

On the day this news was published, NUVL gained 0.98%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., Aug. 29, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Morgan Stanley 22^nd Annual Global Healthcare Conference on Thursday, September 5, 2024, at 1:05 p.m. ET in NYC.

A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.

About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-the-morgan-stanley-22nd-annual-global-healthcare-conference-302233283.html

SOURCE Nuvalent, Inc.

FAQ

When is Nuvalent (NUVL) participating in the Morgan Stanley Healthcare Conference?

Nuvalent (NUVL) is participating in the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024, at 1:05 p.m. ET in New York City.

Who will represent Nuvalent (NUVL) at the Morgan Stanley Healthcare Conference?

James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will represent Nuvalent (NUVL) at the Morgan Stanley Healthcare Conference.

How can I watch Nuvalent's (NUVL) presentation at the Morgan Stanley Healthcare Conference?

A live webcast of Nuvalent's (NUVL) presentation will be available in the Investors section of the company's website at www.nuvalent.com. The webcast will be archived for 30 days following the presentation.

What is the focus of Nuvalent's (NUVL) research and development?

Nuvalent (NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer.